Intrapleural infusion of activated macrophages and γ-interferon in malignant pleural mesothelioma -: A phase II study

Study objectives: Intrapleural immunotherapy has shown some activity in patients with malignant mesothelioma. We conducted a multicentric pilot phase II study to evaluate the tolerance and the activity of intrapleurally infused autologous human activated macrophages (AMPhi) in patients with stage IA, IB, and IIA malignant pleural mesothelioma (MPM). Design: AM(D derived from in vitro monocyte culture were infused into the pleura of patients every week for 8 consecutive weeks. Each infusion was followed 3 days later by an intrapleural injection of 9 millions units of gamma-interferon (gamma-IFN) in an attempt to prolong the in vivo activation of infused AMPhi. Response was assessed by CT scan and thoracoscopy when possible. If the patient's disease progressed after A-NI(D treatment, an additional treatment was left to the choice of the investigator. Patients: Nineteen patients with histologically proven stage IA, IB, or IIA MPM were enrolled. Two patients were excluded before any AMPhiD infusion because of complications impeding infusion. Seventeen patients were actually treated. After completion of the AMPhi cellular therapy, 10 patients were treated with chemotherapy as their diseases progressed. Results: The overall response rate of patients actually treated was 14%. When including the two patients enrolled but not treated, the overall response "in intention to treat" was 11%; two patients had a partial response, with a duration of response of 30 months and 3 months, respectively. One patient, who could not be evaluated by thoracoscopy because of pleural symphysis, is still alive without any clinical or radiologic sign of disease 69 months after treatment. No major adverse effects were observed during the infusion of either AMPhi or gamma-IFN, and there was no interruption of treatment because of toxicity. However, symphysis was observed in 7 of 14 patients who received the complete treatment. The median survival of patients actually treated, including those who received chemotherapy after AMPhi, was 29.2 months. Conclusion: Combined infusion of A-MPhi and gamma-IFN was well tolerated in patients with MPM; however, it had limited antitumor activity.